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ABSTRACT
Objective Mitochondrial disturbances of energy-
generating systems in childhood are a heterogeneous 
group of disorders. The aim of this multi-site survey 
was to characterise the natural course of a novel 
mitochondrial disease with ATP synthase defi ciency and 
mutation in the TMEM70 gene.
Methods Retrospective clinical data and metabolic 
profi les were collected and evaluated in 25 patients 
(14 boys, 11 girls) from seven European countries with a 
c.317-2A→G mutation in the TMEM70 gene.
Results Severe muscular hypotonia (in 92% of 
newborns), apnoic spells (92%), hypertrophic 
cardiomyopathy (HCMP; 76%) and profound 
lactic acidosis (lactate 5–36 mmol/l; 92%) with 
hyperammonaemia (100–520 µmol/l; 86%) were 
present from birth. Ten patients died within the fi rst 
6 weeks of life. Most patients surviving the neonatal 
period had persisting muscular hypotonia and developed 
psychomotor delay. HCMP was non-progressive and 
even disappeared in some children. Hypospadia was 
present in 54% of the boys and cryptorchidism in 67%. 
Increased excretion of lactate and 3-methylglutaconic 
acid (3-MGC) was observed in all patients. In four 
surviving patients, life-threatening hyperammonaemia 
occurred during childhood, triggered by acute 
gastroenteritis and prolonged fasting.
Conclusions ATP synthase defi ciency with mutation 
in TMEM70 should be considered in the diagnosis 
and management of critically ill neonates with early 
neonatal onset of muscular hypotonia, HCMP and 
hypospadias in boys accompanied by lactic acidosis, 
hyperammonaemia and 3-MGC-uria. However, 
phenotype severity may vary signifi cantly. The 
disease occurs frequently in the Roma population and 
molecular-genetic analysis of the TMEM70 gene is 
suffi cient for diagnosis without need of muscle biopsy in 
affected children.
INTRODUCTION
Mitochondrial diseases are a heterogeneous 
group of disorders of the oxidative phosphoryla-
tion system (OXPHOS) composed of four respi-
ratory chain complexes and F1F0-ATP synthase 
(complex V). OXPHOS, as the only exception in 
mammalian cells, is under the genetic control 
of two genomes, nuclear DNA and maternally 
transmitted mitochondrial DNA (mtDNA). In 
mitochondrial diseases, tissues with high energy 
demand such as the brain, muscle and heart, are 
affected most frequently. Recently, an increasing 
Mitochondrial encephalocardio-myopathy with early 
neonatal onset due to TMEM70 mutation
Tomáš Honzík,1 Markéta Tesa˘rová,1 Johannes A Mayr,2 Hana Hansíková,1 Pavel Ješina,1 
Olaf Bodamer,2 Johannes Koch,2 Martin Magner,1 Peter Freisinger,3 Martina Huemer,4 
Olga Kostková,1 Rudy van Coster,5 Stanislav Kmoch,6 Josef Houštêk,7 Wolfgang Sperl,2 
Ji˘ rí Zeman1
number of nuclear genes have been described 
that are related to OXPHOS and their mutations 
result in mitochondrial diseases.1 Substantial 
progress has been also achieved in understand-
ing the molecular basis of severe mitochondrial 
diseases due to isolated deﬁ ciency of ATP syn-
thase, the key enzyme involved in the mito-
chondrial energy conversion and providing most 
of the cellular ATP.
Isolated deﬁ ciency of ATP synthase may 
originate from mutations in mtDNA or nuclear 
genes. The maternally inherited disorders of 
ATP synthase are caused by mtDNA muta-
tions in MTATP62–4 or rarely in MTATP85 genes. 
Their clinical presentation ranges from mild 
What is already known on this topic
▶  An increasing number of children with 
mitochondrial diseases and isolated ATP 
synthase defi ciency have been identifi ed.
▶  Muscular hypotonia, hypertrophic 
cardiomyopathy (HCMP) and lactic acidosis 
are often found in patients with mitochondrial 
disease.
▶  A large number of nuclear genes related 
to OXPHOS have been described whose 
mutations result in mitochondrial disease.
What this study adds
▶  ATP synthase defi ciency due to TMEM70 
mutation is a novel mitochondrial disease with 
neonatal onset with hypotonia, HCMP, lactic 
acidosis, hypospadias, hyperammonaemia 
and 3-methylglutaconic aciduria.
▶  The course of the disease was described in a 
patients with TMEM70 mutation from seven 
European countries.
▶  The distinct phenotype enables molecular-
genetic diagnosis without the need for a 
muscle biopsy.
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In the majority of patients (92%), muscular hypotonia, 
apnoic spells and acute metabolic distress characterised by lac-
tic acidosis and hyperammonaemia (86%) were present from 
birth. Artiﬁ cial ventilation was necessary in 19 neonates. Only 
in two children (P16, P24) was the onset of disease delayed 
until 1–3 months of age. Ten patients died during the ﬁ rst epi-
sode of metabolic disturbance within the ﬁ rst 6 weeks of life. 
Six others died later between 14 months and 4.5 years of age 
following metabolic deterioration as a result of acute respira-
tory infection or gastroenteritis. Interestingly, one of a pair 
of monochorionic–monoamniotic twins (P9) died during the 
neonatal period whereas the other twin (P10) is alive at the age 
of 8 years. Nine patients are alive, the oldest one being 13 years 
old. Failure to thrive and growth retardation (below the third 
percentile) were present in all patients surviving the neonatal 
period. Microcephaly was documented in 59% of all patients. 
Mild cranio-facial dysmorphy with low set ears, a prominent 
nasal bridge and retrognathia were apparent in 16/24 patients. 
In P23 (compound heterozygote), apart from the early neona-
tal onset similar to the other patients, the course of the disease 
was much milder allowing almost normal psychomotor devel-
opment with attendance at a regular school.
Central nervous system
Progressive central nervous impairment was observed in 
most of the patients surviving the neonatal period (table 1), 
but the type and severity of neurological symptoms differed. 
Muscular hypotonia persisted and psychomotor delay devel-
oped in most of the children. Overall visual acuity was normal 
in all children. Neuroimaging was normal in P15, P16, P18, P21 
and P24, mild cerebellar hypoplasia was observed in P10 and 
periventricular cysts in P20.
Heart and liver
HCMP was found in 76% of the patients within the ﬁ rst days 
of life. In most patients, cardiomyopathy was non-progressive. 
During follow-up, a marked regression (P19, P20) or even com-
plete disappearance of HCMP (P15, P10, P23) was observed. 
In three patients (P1, P10, P20), Wolf–Parkinson–White syn-
drome was present. Hepatomegaly due to cardiac-induced liver 
congestion developed in 58% of children during metabolic cri-
ses in the ﬁ rst days of life. In patients surviving beyond the 
neonatal period, neither hepatopathy nor hepatomegaly were 
present.
Urogenital tract
In more than half of the boys, coronal or penile hypospadia 
(54%) and cryptorchidism (67%) were present. In at least 
four families (F7, F9, F10, F14), the hypospadias/cryptorchid-
ism does not occur in other family members and was present 
only in the probands. Additionally, one third of the patients 
had inguinal and/or scrotal hernia, which might be the result 
of prematurity. Renal investigation was performed in ﬁ ve 
patients (P12, P14–16, P18), in all of whom an ultrasound 
revealed marked hyperechogenity of renal parenchyma with 
poor corticomedullar distinction clearly visible at the age of 
6–7 weeks. Generalised hyperaminoaciduria (P12, P14, P18) 
and mild proximal renal tubular acidosis (P12, P18) were pres-
ent. Glomerular or tubular proteinuria was not documented.
Laboratory data
After birth, the initial metabolic disturbance was characterised 
by extreme lactic acidosis (lactate 16±8 mmol/l, range 5–36 
disorders to NARP or Leigh syndrome (symmetrical necrotic 
lesions in basal ganglia and/or the brain stem) and typically 
depends on the level of mtDNA heteroplasmy. The ﬁ rst ATP 
synthase deﬁ ciency of nuclear genetic origin was described 
by our group in 1999.6 Since then an increasing number 
of children with ATP synthase deﬁ ciency have revealed a 
similar phenotype with early neonatal onset of hypotonia, 
hypertrophic cardiomyopathy (HCMP), lactic acidosis and 
3-methylglutaconic aciduria (3-MGC-uria).7 8 In 2004, the 
ﬁ rst pathogenic mutation in the nuclear encoded gene ATP12 
was identiﬁ ed9 in a patient with dysmorphic features and 
cortical atrophy. In 2008, we identiﬁ ed for the ﬁ rst time in 
23 ATP synthase- deﬁ cient patients mutation c.317-2A→G 
in the TMEM70 gene.10 Furthermore, we have proved that 
TMEM70 is indispensable for ATP synthase biogenesis. 
Recently, three other children from one family with the 
same TMEM70 mutation have been described,11 thus demon-
strating unexpectedly high incidence of this genetic disorder 
that appears to be the most frequent cause of mitochondrial 
diseases due to diminished biosynthesis of ATP synthase.
The aim of our study is detailed retrospective characterisa-
tion of the phenotype in a genetically homogeneous group of 
25 patients with c.317-2A→G mutation in the TMEM70 gene 
with respect to the natural course of the disease and the long-
term prognosis. As we wished to describe frequent symptoms 
of TMEM70 patients and metabolic proﬁ les, speciﬁ c attention 
was paid to the co-occurrence of hypospadia, hyperammonae-
mia, lactic acidosis and 3-MGC-uria.
PATIENTS AND METHODS
Patients
Twenty ﬁ ve children from seven European countries (14 
boys, 11 girls) with ATP synthase deﬁ ciency due to TMEM70 
mutations were included. Twenty four patients were homo-
zygous for the c.317-2A→G mutation in the TMEM70 gene 
and one patient (P23) was compound heterozygote c.[317-
2A→G]+[118_119insGT].10 Twenty four patients from 21 fam-
ilies were of Roma ethnic origin. Three families (F1, F14, F17) 
were consanguineous. Patient P23 was from a non-consanguin-
eous non-Roma family. A diagnosis of ATP synthase deﬁ ciency 
(activity <30% of controls) with pronounced reduction of the 
ATP synthase content was made by measuring the activity of 
OXPHOS complexes and by BN-PAGE. Furthermore, mildly 
decreased activity of complex I (80–90% of controls) was 
observed in 10 out of 16 available muscle samples. To provide 
a complete overview of the phenotype, data from 10 patients 
reported earlier as indicated in table 1 have been included and 
updated.
Ethics
The study was approved by the Committees of Medical 
Ethics at all collaborating institutions. Informed consent was 
obtained from parents.
RESULTS
Natural course of the disease
The age of onset, the clinical symptoms and the course of the 
disease in the 25 patients are summarised in table 1. Overall, 
68% of patients were delivered prematurely and intrauter-
ine growth retardation (IUGR) was present in 58%. The 
mean±SD birth weight was 2040±471 g (range 1150–3080 g) 
and mean±SD gestation age was 36±2.6 weeks (range 31–41 
weeks).
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Table 1 Main clinical symptoms in 25 patients with TMEM70 mutation
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1 F1 <1 week + Died + + Died Died Died Died Died + + + + 10 days  
2 F2 <1 week − Died + + Died Died Died Died Died − + Girl Girl 2 days
3 F2 <1 week + Died − + Died Died Died Died Died + + + 12 days P26, 7
4 F2 <1 week + + + + Moderate NA NA NA NA + + 3 years
5 F3 <1 week − Died − + Died Died Died Died Died + + Girl Girl 12 days P97
6 F4 <1 week − Died − + Died Died Died Died Died + − − − 1 day
7 F5 <1 week − Died − + Died Died Died Died Died + − Girl Girl 4 days
8 F6 <1 week + Died NA + Died Died Died Died Died + Girl Girl 2 days
9 F7 <1 week + + NA + Died Died Died Died Died + + − + 1 month P77
10 F7 <1 week + + + + Moderate + − + + − + − − Alive/
8 years
P87
11 F8 <1 week − + + + Died Died Died Died Died + + − + 6 weeks
12 F9 <1 week + + + + Moderate NA NA − − − + + + 18 months
13 F10 <1 week + + + + Moderate + + − − − + + + 4.5 years P107
14 F10 <1 week + + + + Moderate + + − − − − + + 3 years
15 F11 <1 week + + + + Severe + + − + + + Girl Girl Alive/
13 years
P67
16 F12 <3 months + + + + Moderate + − − − − − Girl Girl Alive/
5 years
P117
17 F13 <1 week NA + NA + Moderate NA NA NA NA + + Girl Girl Alive/
2.5 years
18 F14 <1 week + + + + Moderate + − − − + + + + 3 years
19 F15 <1 week + + + + Moderate − − − + + + Girl Girl Alive/
6 years
P197
20 F16 <1 week + + + + Moderate − − − + − + − + Alive/
5 years
P147
21 F17 <1 week + + − + Moderate + − + − − − Girl Girl Alive/
9 years
P37
22 F18 <1 week + + − + Moderate − − − + − + + − Alive/
4 years
23* F19 <1 week − + − − − − − − − − + Girl Girl Alive/
10 years
24 F20 <2 months − + − + − − − − − + + Girl Girl 14 months
25 F21 <1 week − Died − + Died Died Died Died − + − − − 3 days
Total   16/24 17/17 13/22 24/25 13/15 7/12 3/12 2/13 5/14 14/24 19/25 7/13 8/12 16/25  
CPEO, chronic progressive external ophthalmoplegia; Died, died too early for evaluation of the symptom; FTT, failure to thrive; GR, growth retardation; HCMP, hypertrophic 
cardiomyopathy; NA, data not available.
*P23 was compound heterozygote for mutations c.317-2A→G/c.118_119insGT in TMEM70.
mmol/l, controls <2.3 mmol/l; base excess −6 to −30 mmol/l). 
Patients surviving 6 weeks presented with intermittent hyper-
lactacidaemia (1.6–22.9 mmol/l). Serum alanine was increased 
in 88% (520–3938 μmol/l, controls <500) and uric acid in 92% 
(420–703 μmol/l, controls <340) of examined cases. Creatine 
kinase was increased intermittently (1–30 μkat/l, controls 
<2.8) in 12 out of 14 investigated children.
Altogether, 92 values of lactate measured spectrophoto-
metrically and 77 urinary organic acid proﬁ les determined by 
gas chromatography–mass spectrometry were available (1–10 
from each patient). In all patients, intermittently increased 
excretion of lactate (13–68 846 mmol/mol creatinine, con-
trols <60; 36% of samples within control range) and 3-MGC 
(<15–460 mg/g creatinine, controls <15; 9% of samples within 
control range) were observed. 3-Methylglutaric acid (22–361 
mg/g creatinine, controls <15) and Krebs cycle intermediates 
were raised in 70% of the proﬁ les. In most patients, normal 
or only mild elevation of urinary excretion of orotic acid was 
found (1.7–8.8 mmol/mol creatinine, controls <3.5).
Hyperammonaemic crises
In 12 out of 14 children, hyperammonaemia (100–520 μmol/l, 
controls <80) was present during acute metabolic disturbance 
after birth. Six of these children died. In patients P10, P14, P16 
and P18, hyperammonaemia (226–870 μmol/l, neonatal con-
trols <80) occurred during childhood triggered by acute gastro-
enteritis with prolonged fasting. At the time of admission to 
the metabolic unit, all four children were sleepy and apathetic, 
and in one child artiﬁ cial ventilation was necessary. Liver func-
tion tests as well as acylcarnitine proﬁ les were normal. Table 2 
summarises the laboratory data of these patients at admission 
and compares these with data obtained during regular check-
ups in the outpatient clinic. Except for pronounced ketonuria, 
urinary excretion of the organic acids including 3-MGC was 
not altered during acute crisis. In patients P14 and P18, the 
hyperammonaemia progressed further, and despite therapeu-
tic efforts, these children died.
Low glucose tolerance (max 3–4 mg/kg/min) and further 
aggravation of hyperlactacidaemia was observed. Fat emulsion 
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tolerance was preserved enabling lipid supplementation (3.5 g/
kg/day) in all patients with gastroenteritis.
DISCUSSION
Our study presents for the ﬁ rst time a detailed retrospective 
analysis of the phenotype and metabolic proﬁ les in a genet-
ically homogenous group of 25 patients with mutations in 
the TMEM70 gene, coding for a novel factor of ATP synthase 
biogenesis. The TMEM70 mutation c.317-2A→G, found in all 
patients, leads to aberrant splicing and loss of the TMEM70 
transcript.10 In the compound heterozygote patient (P23), the 
frame-shift mutation c.118_119insGT identiﬁ ed on the second 
allele results in a truncated TMEM70 protein Ser40CysfsX11.
TMEM70 deﬁ ciency is characterised by early neonatal 
onset of hypotonia, HCMP and apnoic spells within hours 
after birth accompanied by lactic acidosis, hyperammonaemia 
and 3-MGC-uria. Ten patients died within the ﬁ rst 6 weeks 
of life and six others died during the toddler and preschool 
period. Since there were no differences regarding age of onset 
and severity of clinical symptoms among our patients, one 
might conclude that management in the intensive care unit is 
crucial for survival beyond the neonatal period. However, the 
extremely different survival outcomes of the monochorionic–
monoamniotic twins might also indicate the inﬂ uence of other 
factors. Early onset is a common feature of other nuclearly 
encoded defects of mitochondrial ATP synthasome9 12 13 and 
other OXPHOS deﬁ ciencies.14 Nevertheless, early neo natal 
onset with distinctive symptoms and biochemical proﬁ les 
seems to be crucial for the diagnosis of TMEM70 deﬁ ciency. 
Furthermore, molecular-genetic analysis of the TMEM70 gene 
is sufﬁ cient for diagnosis and analysis of the activity and 
amount of ATP synthase in biopsy samples can be restricted 
to TMEM70-negative cases.
In patients surviving 6 weeks, the principle clinical symp-
toms were functional impairment of the brain, muscle and 
heart. However, the severity of symptoms together with psy-
chomotor delay, failure to thrive and growth retardation may 
vary signiﬁ cantly.11
Although cardiomyopathy is found in other OXPHOS 
disorders,15–17 defects of ATP synthasome12 13 and Barth 
syndrome,18 19 its onset and severity varies considerably. 
HCMP was found in 76% of TMEM70 patients, and simi-
larly to Barth syndrome and PiC deﬁ ciency,12 20 21 it was pre-
sent since birth. In the surviving TMEM70-deﬁ cient patients, 
the heart impairment has a benign course. In fact, in three of 
our patients the HCMP disappeared at the age of 8, 10 and 13 
years, respectively. Similarly, improvement in cardiac function 
was described in Barth syndrome patients22 and one patient 
with complex I deﬁ ciency.23 However, the disappearance of 
HCMP or stabilisation of cardiac functions might be orches-
trated by AMP-activated protein kinase, a key regulator of cel-
lular energy homeostasis.24–27
Table 2 A comparison of biochemical data from four patients obtained during regular check-up in an outpatient clinic and during hyperammonaemic epi-
sodes at the time of admission to the metabolic unit
 Patient 10 Patient 14 Patient 16 Patient 18
ControlsCheck-up
Admission 
(age 7 years) Check-up
Admission 
(age 3 years) Check-up
Admission 
(age 5 years) Check-up
Admission 
(age 6 years)
Blood
 Ammonia 39–49 870 ND 520 11–32 296 ND 226 <60 µmol/l
 Lactate 1.6 16 4–6 9.7 1.2–3.9 9.6 2.1–4.9 16 <2.3 
mmol/l
 Base excess −2 −25 −1 to −4.8 −20 −2.1 to −6 −24.2 −3.1 to −4.4 −23 0±2 mmol/l
 Glycaemia 4.4 2.5 4.5–5.6 3.5 4.5–6.8 2.5 4.3–6.1 3,0 3.3–5.2 
mmol/l
 pH 7.4–7.46 7.16 7.44–7.59 7.17 7.43–7.47 7.14 7.41–7.46 7.09 7.36–7.44
 Cholesterol 2.59 ND 3.26 3.45 5.68 5 2.64 2.36 2.6–4.8 
mmol/l
 TG 0.75 0.61 1.02 0.15 1.75 0.84 0.78 0.77 1.0–1.64 
mmol/l
 Alanine 192–1039 7173 408–890 2772 489–899 1681 350–550 3982 150–500 
µmol/l
 Glu+Gln 256–1008 2000 262–716 862 310–614 988 415–706 1534 200–900 
µmol/l
 Arginine 22–162 22–83 42–86 33 51–133 60 27–124 90 10–150 
µmol/l
 Ornithine 25–94 64 13 47 61 28 32 90 30–200 
µmol/l
 Citrulline 7–29 151 8–28 39 7–25 13 5–50 143 5–50 µmol/l
Urine
 Lactate 14–144 68846 96–6446 10257 16–244 3952 53–3095 3297 <60 
mmol/mol 
creatinine
 3-OH butyrate Neg 10786 10–240 11730 Neg 5023 Neg 3980 <100 mg/g 
creatinine
 Acetoacetate Neg 3650 10–21 2036 Neg 1540 Neg 923 <15 mg/g 
creatinine
 Orotic acid 5.5 3.7 1.73 4.3 2.4 1.2 3.4–8.8 5.8 <3.5 
mmol/mol 
creatinine
Gln, glutamine; Glu, glutamate; ND, not determined; Neg, negative; TG, triglycerides.
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Hypospadias and/or cryptorchidism are not normally 
observed in OXPHOS disorders. Interestingly, these congen-
ital defects were present in more than 50% of the boys with 
TMEM70 mutation. The incidence of hypospadias is esti-
mated at 3.8 per 1000 male newborns28 and is similar between 
Caucasians and other ethnic groups. A signiﬁ cant association 
between hypospadias and IUGR was described,29 but in our 
patients hypospadias and IUGR did not completely overlap. 
The higher incidence of hypospadia and/or cryptorchidism in 
the patients studied suggests a possible link with TMEM70 
deﬁ ciency. TMEM70-deﬁ cient cells display increased mito-
chondrial membrane potential resulting in increased produc-
tion of reactive oxygen species30 that may alter signalling 
pathways during the complex developmental process of exter-
nal male genitalia formation.
Besides hyperlactaciduria, 3-MGC-uria is the most con-
stant laboratory ﬁ nding in patients with TMEM70 mutations, 
although other organic acids may be also elevated. Nonetheless, 
repeated analyses of 3-MGC revealed ﬂ uctuations in its level. 
To date, ﬁ ve distinct types of 3-MGC-uria have been deﬁ ned.31 
Interestingly, three types of 3-MGC-uria, namely Barth syn-
drome (type II, mutation in the TAZ gene), Costeff syndrome 
(type III, mutation in OPA3) and type V caused by mutations 
in DNAJC19, and two syndromes of type IV (TMEM70 deﬁ -
ciency, ANT1 deﬁ ciency) are caused by defective proteins 
related to the inner mitochondrial membrane. Moreover, 
all these syndromes are characterised by cardiomyopathy. 
Additionally, hypospadias and/or cryptorchidism are present 
in TMEM70 and DNAJC19 deﬁ ciency.
Hyperammonaemia is a frequent ﬁ nding in TMEM70-
deﬁ cient patients. Life-threatening hyperammonaemia was 
described only in a small number of patients with OXPHOS 
disorders and Barth syndrome.20 21 In our study, hyperam-
monaemia was present in 12 children after birth and four 
patients developed hyperammonaemia again during acute 
gastroenteritis with prolonged fasting. In the early phase 
of catabolism due to fasting, there is marked up-regulation 
of genes for urea cycle enzymes and the capacity for liver 
ATP synthesis is strongly enhanced.32 Apart from its other 
cellular roles, ATP is crucial for preserving the functional 
urea cycle as two of its enzymes (carbamoyl-phosphate 
synthase (CPS1) and argininosuccinate synthase) are ATP 
dependent.
A reduced tolerance of sugars and good tolerance of fat 
emulsions were observed. Administration of fats as a main 
source of energy to avoid catabolism has led to normalisation 
of critical metabolic acidosis and to a reduction in hyperlact-
acidaemia. Based on our experience with TMEM70-deﬁ cient 
patients, similarly to other mitochondrial diseases,33 optimal 
nutritional status with frequent feeding to minimise catabo-
lism is essential to prevent a life-threatening metabolic crisis.
Although our patients came from seven European countries, 
all 24 homozygotes for c.317-2A→G in TMEM70 were of Roma/
Gypsy origin. Approximately 10 million Roma living in Europe 
form an ethnic group with a common origin.34 Genotyping 
data available in some TMEM70-deﬁ cient families10 suggest 
that some of the families may be related back to the third to 
sixth generations. Based on this information and considering 
that we analysed the majority of patients known and avail-
able, it appears that isolated ATP synthase deﬁ ciency caused 
by mutation c.317-2A→G in TMEM70 is a defect occurring fre-
quently due to a founder allele effect in the Roma population.10 
35 However, other TMEM70 mutations probably occur in other 
ethnic groups, as might be concluded from our patient P23.
CONCLUSION
We characterised the natural course of the disease together 
with detailed metabolic proﬁ les in 25 patients with ATP 
synthase deﬁ ciency due to TMEM70 mutation c.317-2A→G, 
which occurs frequently in the Roma population due to a 
founder allele effect. Early neonatal onset of severe muscular 
hypotonia, HCMP and hypospadia in boys accompanied by 
lactic acidosis, hyperammonaemia and 3-MGC-uria charac-
terise the phenotype. Despite being due to the same TMEM70 
mutation, the severity of the phenotype may vary signiﬁ -
cantly. However, TMEM70 deﬁ ciency should be considered in 
the diagnosis and management of critically ill neonates. Early 
diagnosis of TMEM70 deﬁ ciency together with appropriate 
intensive care and optimal nutrition to prevent catabolism 
may improve the life expectancy of affected patients.
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